| Dr Arnold S Ravick, DPM | |
|
1145 19th Street, N.w., Suite 409, Washington, DC 20036-3716 | |
| (202) 223-0500 | |
| (202) 296-2531 |
| Full Name | Dr Arnold S Ravick |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 45 Years |
| Location | 1145 19th Street, N.w., Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003870841 | NPI | - | NPPES |
| 480013906 | Other | DC | RR MEDICARE INDIVIDUAL PROVIDER # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | PO326 (District Of Columbia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| George Washington University Medical Faculty Associates | 4082528898 | 651 |
News Archive
Medisse, a medical device company focused on the development of a new generation of resorbable flexible implants, announced today that it has successfully completed the biocompatibility evaluation of its novel resorbable FlexiSurge biomaterial in accordance with the international ISO 10993 standards.
The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
Brazilian scientists say they have discovered how humans choose their partners - they say opposites attract and genetics influence how a person chooses a partner.
Osteologix Holdings, PLC declared a dividend of Euro 0.06 per sharepayable to shareholders of record on December 19, 2011. The payment date will be February 15, 2012.
› Verified 6 days ago
| Provider Name | Medical Faculty Associates, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1417990581 PECOS PAC ID: 4082528898 Enrollment ID: O20031117000341 |
News Archive
Medisse, a medical device company focused on the development of a new generation of resorbable flexible implants, announced today that it has successfully completed the biocompatibility evaluation of its novel resorbable FlexiSurge biomaterial in accordance with the international ISO 10993 standards.
The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
Brazilian scientists say they have discovered how humans choose their partners - they say opposites attract and genetics influence how a person chooses a partner.
Osteologix Holdings, PLC declared a dividend of Euro 0.06 per sharepayable to shareholders of record on December 19, 2011. The payment date will be February 15, 2012.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Arnold S Ravick, DPM 1145 19th St Nw, Suite #409, Washington, DC 20036-3701 Ph: (301) 455-3566 | Dr Arnold S Ravick, DPM 1145 19th Street, N.w., Suite 409, Washington, DC 20036-3716 Ph: (202) 223-0500 |
News Archive
Medisse, a medical device company focused on the development of a new generation of resorbable flexible implants, announced today that it has successfully completed the biocompatibility evaluation of its novel resorbable FlexiSurge biomaterial in accordance with the international ISO 10993 standards.
The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
Brazilian scientists say they have discovered how humans choose their partners - they say opposites attract and genetics influence how a person chooses a partner.
Osteologix Holdings, PLC declared a dividend of Euro 0.06 per sharepayable to shareholders of record on December 19, 2011. The payment date will be February 15, 2012.
› Verified 6 days ago
Dr. Andrew Lewis Carver, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1040 17th Street Nw, Washington, DC 20036 Phone: 202-296-2424 Fax: 202-318-8197 | |
Foot And Ankle Wellness Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1160 Varnum St Ne Ste 200, Washington, DC 20017 Phone: 202-635-8306 | |
Michael Sean Stempel, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2150 Pennsylvania Ave Nw, Dept. Of Medicine, Washington, DC 20037 Phone: 202-741-3333 | |
Dr. Harold Bruce Glickman, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 5513 Connecticut Ave Nw, Suite 210, Washington, DC 20015 Phone: 202-833-9797 Fax: 202-833-9799 | |
Dr. Barbara Anita Clorey, PA-C Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1350 Connecticut Ave Nw Ste 1250, Washington, DC 20036 Phone: 202-627-1901 | |
Dr. Sheldon I. Laps Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1234 19th St Nw, Suite 610, Washington, DC 20036 Phone: 202-223-9020 Fax: 202-728-0874 |